RATIONALE: Idiopathic or heritable pulmonary arterial hypertension is characterized by loss and obliteration of lung vasculature. Endothelial cell dysfunction is pivotal to the pathophysiology, but different causal mechanisms may reflect a need for patient-tailored therapies. OBJECTIVES: Endothelial cells differentiated from induced pluripotent stem cells were compared with pulmonary arterial endothelial cells from the same patients with idiopathic or heritable pulmonary arterial hypertension, to determine whether they shared functional abnormalities and altered gene expression patterns that differed from those in unused donor cells. We then investigated whether endothelial cells differentiated from pluripotent cells could serve as surrogates to test emerging therapies. METHODS: Functional changes assessed included adhesion, migration, tube formation, and propensity to apoptosis. Expression of bone morphogenetic protein receptor type 2 (BMPR2) and its target, collagen IV, signaling of the phosphorylated form of the mothers against decapentaplegic proteins (pSMAD1/5), and transcriptomic profiles were also analyzed. MEASUREMENTS AND MAIN RESULTS: Native pulmonary arterial and induced pluripotent stem cell-derived endothelial cells from patients with idiopathic and heritable pulmonary arterial hypertension compared with control subjects showed a similar reduction in adhesion, migration, survival, and tube formation, and decreased BMPR2 and downstream signaling and collagen IV expression. Transcriptomic profiling revealed high kisspeptin 1 (KISS1) related to reduced migration and low carboxylesterase 1 (CES1), to impaired survival in patient cells. A beneficial angiogenic response to potential therapies, FK506 and Elafin, was related to reduced slit guidance ligand 3 (SLIT3), an antimigratory factor. CONCLUSIONS: Despite the site of disease in the lung, our study indicates that induced pluripotent stem cell-derived endothelial cells are useful surrogates to uncover novel features related to disease mechanisms and to better match patients to therapies.
RATIONALE: Idiopathic or heritable pulmonary arterial hypertension is characterized by loss and obliteration of lung vasculature. Endothelial cell dysfunction is pivotal to the pathophysiology, but different causal mechanisms may reflect a need for patient-tailored therapies. OBJECTIVES: Endothelial cells differentiated from induced pluripotent stem cells were compared with pulmonary arterial endothelial cells from the same patients with idiopathic or heritable pulmonary arterial hypertension, to determine whether they shared functional abnormalities and altered gene expression patterns that differed from those in unused donor cells. We then investigated whether endothelial cells differentiated from pluripotent cells could serve as surrogates to test emerging therapies. METHODS: Functional changes assessed included adhesion, migration, tube formation, and propensity to apoptosis. Expression of bone morphogenetic protein receptor type 2 (BMPR2) and its target, collagen IV, signaling of the phosphorylated form of the mothers against decapentaplegic proteins (pSMAD1/5), and transcriptomic profiles were also analyzed. MEASUREMENTS AND MAIN RESULTS: Native pulmonary arterial and induced pluripotent stem cell-derived endothelial cells from patients with idiopathic and heritable pulmonary arterial hypertension compared with control subjects showed a similar reduction in adhesion, migration, survival, and tube formation, and decreased BMPR2 and downstream signaling and collagen IV expression. Transcriptomic profiling revealed high kisspeptin 1 (KISS1) related to reduced migration and low carboxylesterase 1 (CES1), to impaired survival in patient cells. A beneficial angiogenic response to potential therapies, FK506 and Elafin, was related to reduced slit guidance ligand 3 (SLIT3), an antimigratory factor. CONCLUSIONS: Despite the site of disease in the lung, our study indicates that induced pluripotent stem cell-derived endothelial cells are useful surrogates to uncover novel features related to disease mechanisms and to better match patients to therapies.
Entities:
Keywords:
CES1; KISS1; SLIT3; endothelial cells; precision medicine
Authors: Mingxia Gu; Nicholas M Mordwinkin; Nigel G Kooreman; Jaecheol Lee; Haodi Wu; Shijun Hu; Jared M Churko; Sebastian Diecke; Paul W Burridge; Chunjiang He; Frances E Barron; Sang-Ging Ong; Joseph D Gold; Joseph C Wu Journal: Eur Heart J Date: 2014-11-02 Impact factor: 29.983
Authors: Ivana Fantozzi; Oleksandr Platoshyn; Ada H Wong; Shen Zhang; Carmelle V Remillard; Manohar R Furtado; Olga V Petrauskene; Jason X-J Yuan Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-06-30 Impact factor: 5.464
Authors: Christopher J Rhodes; Hogune Im; Aiqin Cao; Jan K Hennigs; Lingli Wang; Silin Sa; Pin-I Chen; Nils P Nickel; Kazuya Miyagawa; Rachel K Hopper; Nancy F Tojais; Caiyun G Li; Mingxia Gu; Edda Spiekerkoetter; Zhaoying Xian; Rui Chen; Mingming Zhao; Mark Kaschwich; Patricia A Del Rosario; Daniel Bernstein; Roham T Zamanian; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch Journal: Am J Respir Crit Care Med Date: 2015-08-01 Impact factor: 21.405
Authors: Nils P Nickel; Edda Spiekerkoetter; Mingxia Gu; Caiyun G Li; Hai Li; Mark Kaschwich; Isabel Diebold; Jan K Hennigs; Ki-Yoon Kim; Kazuya Miyagawa; Lingli Wang; Aiqin Cao; Silin Sa; Xinguo Jiang; Raymond W Stockstill; Mark R Nicolls; Roham T Zamanian; Richard D Bland; Marlene Rabinovitch Journal: Am J Respir Crit Care Med Date: 2015-06-01 Impact factor: 21.405
Authors: Allison E Ashley-Koch; Laine Elliott; Melanie E Kail; Laura M De Castro; Jude Jonassaint; Terry L Jackson; Jennifer Price; Kenneth I Ataga; Marc C Levesque; J Brice Weinberg; Eugene P Orringer; Ann Collins; Jeffery M Vance; Marilyn J Telen Journal: Blood Date: 2008-01-10 Impact factor: 22.113
Authors: B Janssens; S Goossens; K Staes; B Gilbert; J van Hengel; C Colpaert; E Bruyneel; M Mareel; F van Roy Journal: J Cell Sci Date: 2001-09 Impact factor: 5.285
Authors: Caiyun G Li; Cathal Mahon; Nathaly M Sweeney; Erik Verschueren; Vivek Kantamani; Dan Li; Jan K Hennigs; David P Marciano; Isabel Diebold; Ossama Abu-Halawa; Matthew Elliott; Silin Sa; Feng Guo; Lingli Wang; Aiqin Cao; Christophe Guignabert; Julie Sollier; Nils P Nickel; Mark Kaschwich; Karlene A Cimprich; Marlene Rabinovitch Journal: Cell Rep Date: 2019-01-29 Impact factor: 9.423
Authors: Alice M Goyanes; Aigul Moldobaeva; Mery Marimoutou; Lidenys C Varela; Lan Wang; Laura F Johnston; Meena M Aladdin; Grace L Peloquin; Bo S Kim; Mahendra Damarla; Karthik Suresh; Takahiro Sato; Todd M Kolb; Paul M Hassoun; Rachel L Damico Journal: Am J Respir Cell Mol Biol Date: 2020-04 Impact factor: 6.914
Authors: Fedir N Kiskin; C-Hong Chang; Christopher J Z Huang; Baraa Kwieder; Christine Cheung; Benjamin J Dunmore; Felipe Serrano; Sanjay Sinha; Nicholas W Morrell; Amer A Rana Journal: Am J Respir Crit Care Med Date: 2018-07-15 Impact factor: 21.405
Authors: Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu Journal: Am J Respir Crit Care Med Date: 2018-07-01 Impact factor: 21.405
Authors: Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-02-08 Impact factor: 5.464
Authors: Mark E Orcholski; Artyom Khurshudyan; Elya A Shamskhou; Ke Yuan; Ian Y Chen; Sean D Kodani; Christophe Morisseau; Bruce D Hammock; Ellen M Hong; Ludmila Alexandrova; Tero-Pekka Alastalo; Gerald Berry; Roham T Zamanian; Vinicio A de Jesus Perez Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-05-04 Impact factor: 5.464